CY1113724T1 - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Gastrointestinal Disorders - Google Patents

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Gastrointestinal Disorders

Info

Publication number
CY1113724T1
CY1113724T1 CY20131100179T CY131100179T CY1113724T1 CY 1113724 T1 CY1113724 T1 CY 1113724T1 CY 20131100179 T CY20131100179 T CY 20131100179T CY 131100179 T CY131100179 T CY 131100179T CY 1113724 T1 CY1113724 T1 CY 1113724T1
Authority
CY
Cyprus
Prior art keywords
gastritis
treatment
pharmaceutical composition
phospholipids
gastrointestinal disorders
Prior art date
Application number
CY20131100179T
Other languages
Greek (el)
Inventor
Salvatore Bellinvia
Laura Martelli
Mario Martelli
Original Assignee
Giuliani S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani S.P.A. filed Critical Giuliani S.P.A.
Publication of CY1113724T1 publication Critical patent/CY1113724T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Η εφεύρεση σχετίζεται με μία φαρμακευτική σύνθεση που βασίζεται σε μια δραστική ουσία, όπως κυρίως η Σουκραλφάτη, για τη θεραπεία διαταραχών που σχετίζονται με γαστρεντερικό ερεθισμό, όπως γαστρικά έλκη, δωδεκαδακτυλικά έλκη, οξεία γαστρίτιδα, συμπτωματική χρόνια γαστρίτιδα, γαστροπάθεια που σχετίζεται με αντιφλεγμονώδη, οισοφαγίτιδα εκ παλινδρόμησης, που χαρακτηρίζεται στο ότι περιλαμβάνει ένα ή περισσότερα φωσφολιπίδια. Η εφεύρεση σχετίζεται με τη χρήση των φωσφολιπιδίων σε συνδυασμό με την εν λόγω δραστική ουσία που πρόκειται να χορηγηθεί δια του στόματος για τη βελτίωση της γευστικότητάς της και με τη χρήση των φωσφολιπιδίων σε συνδυασμό με την εν λόγω δραστική ουσία που πρόκειται να χορηγηθεί δια του στόματος για τη θεραπεία διαταραχών γαστρεντερικού ερεθισμού και για να βελτιώσει συνεργιστικά την αντί-ελκωτική επίδραση της.The invention relates to a pharmaceutical composition based on an active substance, such as sucralfate, for the treatment of gastrointestinal irritation disorders, such as gastric ulcers, duodenal ulcers, acute gastritis, symptomatic chronic gastritis, gastrointestinal gastritis, gastritis regression, characterized in that it comprises one or more phospholipids. The invention relates to the use of phospholipids in combination with said active ingredient to be orally administered to improve its taste and the use of phospholipids in combination with said active ingredient to be administered orally. to treat gastrointestinal irritation disorders and synergistically improve its anti-ulcerative effect.

CY20131100179T 2008-09-17 2013-02-27 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Gastrointestinal Disorders CY1113724T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425607A EP2172203A1 (en) 2008-09-17 2008-09-17 Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
EP09736868A EP2344166B1 (en) 2008-09-17 2009-09-16 Pharmaceutical composition for the treatment of gastrointestinal irritation disorders

Publications (1)

Publication Number Publication Date
CY1113724T1 true CY1113724T1 (en) 2016-06-22

Family

ID=40279068

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100179T CY1113724T1 (en) 2008-09-17 2013-02-27 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Gastrointestinal Disorders

Country Status (10)

Country Link
EP (2) EP2172203A1 (en)
CY (1) CY1113724T1 (en)
DK (1) DK2344166T3 (en)
ES (1) ES2400111T3 (en)
HR (1) HRP20130112T1 (en)
PL (1) PL2344166T3 (en)
PT (1) PT2344166E (en)
RU (1) RU2497527C2 (en)
SI (1) SI2344166T1 (en)
WO (1) WO2010031785A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120041A1 (en) 2012-02-08 2013-08-09 Dicofarm Spa "PRODUCT BASED ON GLUCOMANNAN AND CHITOSAN PROFITABLE FOR THE TREATMENT OF GASTROESOFAGEO REFLUX"
EP3308773A1 (en) 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
IT202100000059A1 (en) * 2021-01-04 2022-07-04 Nyuma Pharma Srl NEW COMPOSITIONS OF SUCRALFATE IN ALGINATE AND THEIR USE IN THERAPY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064234A (en) * 1974-06-04 1977-12-20 Bristol-Myers Company Methods and pharmaceutical preparation for the treatment of hypercholesterolemia
EP0092121B1 (en) * 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
US4609543A (en) * 1983-11-14 1986-09-02 Nabisco Brands, Inc. Soft homogeneous antacid tablet
GB2195890A (en) * 1986-10-06 1988-04-20 Procter & Gamble Improving palatability of pharmaceutical chewable tablets
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
TW209174B (en) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
ATE192932T1 (en) * 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd FORMULATION CONTAINING AN ANTIBACTERIAL AND AN ANTIULCUS ACTIVE
US5955451A (en) 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
KR20010055274A (en) * 1999-12-10 2001-07-04 김재수 Health augmentation food for the anti fatigue
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
RU2315596C1 (en) * 2006-09-28 2008-01-27 Александр Владимирович Диковский Pharmaceutical composition possessing antiacid and reparative effect, its preparing and using

Also Published As

Publication number Publication date
RU2497527C2 (en) 2013-11-10
PL2344166T3 (en) 2013-05-31
WO2010031785A1 (en) 2010-03-25
RU2011115043A (en) 2012-10-27
PT2344166E (en) 2013-03-05
ES2400111T3 (en) 2013-04-05
EP2344166A1 (en) 2011-07-20
EP2344166B1 (en) 2012-12-05
HRP20130112T1 (en) 2013-03-31
EP2172203A1 (en) 2010-04-07
DK2344166T3 (en) 2013-02-25
SI2344166T1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
CY1120048T1 (en) COMPOSITIONS FOR THE treatment of gastrointestinal inflammation
CY1122966T1 (en) 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER
CY1122472T1 (en) ANTIBODY-DRUG CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
CY1121593T1 (en) TETRAHYDROCANNAVINOL PRODUCTS, COMPOSITIONS INCLUDING TETRAHYDROCANNAVINOL PRODUCTS AND METHODS FOR USING THE SAME
CY1122098T1 (en) ISOCHROMENIUM DERIVATIVES AS PHOSPHOINOSITIDE-3 KINASE INHIBITORS
CY1111478T1 (en) Indication of Progesterone Dosage in the Treatment of Traumatic Brain Injury
CY1121315T1 (en) ORAL COMPOSITIONS OF DEFASIROXY
CY1110495T1 (en) USE OF A NMDA RECEPTOR RECEPTOR FOR INTERVENTION THERAPY Caused by COG
CY1116424T1 (en) ADENINIS PRODUCTION AS RISK RISK
DE602007007991D1 (en) SMALL VOLUME, ORAL, TRANSMUCOSAL DOSAGE FORMS WITH SUFENTANIL FOR PAIN TREATMENT
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
NO20084296L (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an azide
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
CR20170320A (en) MIXTURE OF CARBOXYLIC ACIDS TO TREAT PATIENTS WITH RENAL INSUFFICIENCY
EA201990425A1 (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION
CY1123279T1 (en) CORTICOSTEROIL FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT
CY1120240T1 (en) ORAL TETRACYCLINE COMPONENT TABLET PREPARATION
CY1113724T1 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Gastrointestinal Disorders
CY1117184T1 (en) Β-ARRESTIN BASES AND THEIR COMPOSITIONS AND METHODS thereof
WO2007103540A3 (en) Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
UY39188A (en) IMIDAZOPYRIDAZINES AS IL-17 MODULATORS
CY1116050T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PRONTONE PUMP AND A PRIVILEGE FOR THERAPEUTIC TREATMENT
CY1122882T1 (en) 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
UY31662A1 (en) COMPOSITIONS OF RANITIDINE TABLETS OF ORAL DISINTEGRATION AND ITS METHODS OF ELABORATION.